High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

In conclusion, this study suggested the clinical implication of PHGDH in NSCLC. PHGDH may be a promising therapeutic target in NSCLC. PMID: 27916294 [PubMed - in process]
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research

Related Links:

Publication date: Available online 30 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Kevin C. Lee, Sung-Kiang Chuang
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Ling Wang, Ke Deng, Liang Gong, Liang Zhou, Sapna Sayed, Huan Li, Qi Sun, Zijie Su, Zhongyuan Wang, Shanshan Liu, Huifang Zhu, Jiaxing Song, Desheng Lu
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Pedro Miguel Lacal, Maria Grazia Atzori, Federica Ruffini, Manuel Scimeca, Elena Bonanno, Rosella Cicconi, Maurizio Mattei, Roberta Bernardini, Stefania D’Atri, Lucio Tentori, Grazia Graziani
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Jie Yu, Bingling Zhong, Qingwen Xiao, Lida Du, Ying Hou, Hong-Shuo Sun, Jin-Jian Lu, Xiuping Chen
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Fernanda Carrilho de Menezes, Laertty Garcia de Sousa Cabral, Maria Carla Petrellis, Cyro Festa Neto, Durvanei Augusto Maria
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Mutations in Tumor Protein P53 (p53) are expressed in a variety of human cancers such as cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, and bladder cancer. The p53 protein is involved in determining whether DNA is repaired or the damaged cell undergoes apoptosis – thus acting as a tumor suppressor by regulating cell division. Mutations in the p53 protein can reduce or eliminate its tumor suppressor function or interfere with wild type p53 in...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cervical Cancer | Colon Cancer | Colorectal Cancer | Genetics | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Skin Cancer | Study